CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors
Update: 2025-10-15
Description
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments, one involving the modification of CAR-T technology to overcome the challenges of treating solid tumors, specifically ovarian cancer, and the other, an innovative breast cancer vaccine that trains antigen-specific t-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer. Kumar also talks about the company's robust balance sheet and financial strategy to advance Anixa's clinical developments to commercialization.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
